Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
Bacterial Signaling01:30

Bacterial Signaling

Bacterial signaling can occur within bacteria (intracellular) or between bacteria (intercellular). At times, a group of bacteria behaves like a community. To achieve this, they engage in quorum sensing, the perception of higher cell density that causes changes in gene expression. Quorum sensing involves both extracellular and intracellular signaling. The signaling cascade starts with a molecule called an autoinducer (AI). Individual bacteria produce AIs that move out of the bacterial cell...
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Health of Nations Fund: Financing global drug development.

PLOS global public health·2026
Same author

Estimating the global inventory of deprioritized clinical-stage drug development programs: Toward a market for shelved assets.

Drug discovery today·2026
Same author

Establishing a commercial solution for extremely rare genetic diseases.

Nature biotechnology·2026
Same author

Genetic Targets, Financial Creativity: BridgeBio's Model for Sustainable Drug Development.

Drug discovery today·2025
Same author

Use of Bayesian decision analysis in the design of patient-centered clinical trials for kidney failure devices.

Computers in biology and medicine·2025
Same author

The evolution of discrimination under finite memory constraints.

Scientific reports·2025
Same journal

Author Correction: Improved RNA base editing with guide RNAs mimicking highly edited endogenous ADAR substrates.

Nature biotechnology·2026
Same journal

Unlocking the chemical potential of filamentous fungi using prime editing.

Nature biotechnology·2026
Same journal

A genome-scale CRISPRi perturbation atlas of human induced pluripotent stem cells.

Nature biotechnology·2026
Same journal

Prime editing for precise genome engineering and modulation of fungal metabolism.

Nature biotechnology·2026
Same journal

Retargeted serine integrases for one-step, precise integration of large DNA sequences in human cells.

Nature biotechnology·2026
Same journal

A retargeted recombinase for precise insertion of large DNA.

Nature biotechnology·2026
See all related articles

Related Experiment Video

Updated: May 18, 2026

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
08:50

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Published on: August 16, 2024

Commercializing biomedical research through securitization techniques.

Jose-Maria Fernandez1, Roger M Stein, Andrew W Lo

  • 1MIT Sloan School of Management and Laboratory for Financial Engineering, Cambridge, Massachusetts, USA.

Nature Biotechnology
|October 2, 2012
PubMed
Summary
This summary is machine-generated.

A novel megafund structure can de-risk biomedical innovation by pooling diverse programs. This approach uses debt financing and securitization to attract institutional investment, offering attractive returns for equity and research-backed obligations.

More Related Videos

Autologous Endothelial Progenitor Cell-Seeding Technology and Biocompatibility Testing For Cardiovascular Devices in Large Animal Model
11:49

Autologous Endothelial Progenitor Cell-Seeding Technology and Biocompatibility Testing For Cardiovascular Devices in Large Animal Model

Published on: September 9, 2011

Accessible Silicone Chip-to-Membrane Sealing Procedure for Flexible, Reliable Bonding
06:10

Accessible Silicone Chip-to-Membrane Sealing Procedure for Flexible, Reliable Bonding

Published on: March 20, 2026

Related Experiment Videos

Last Updated: May 18, 2026

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
08:50

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Published on: August 16, 2024

Autologous Endothelial Progenitor Cell-Seeding Technology and Biocompatibility Testing For Cardiovascular Devices in Large Animal Model
11:49

Autologous Endothelial Progenitor Cell-Seeding Technology and Biocompatibility Testing For Cardiovascular Devices in Large Animal Model

Published on: September 9, 2011

Accessible Silicone Chip-to-Membrane Sealing Procedure for Flexible, Reliable Bonding
06:10

Accessible Silicone Chip-to-Membrane Sealing Procedure for Flexible, Reliable Bonding

Published on: March 20, 2026

Area of Science:

  • Biomedical finance
  • Drug development economics
  • Investment strategies

Background:

  • Biomedical innovation faces increasing financial risks and difficulties accessing traditional equity funding.
  • The high cost and complexity of drug development necessitate new financing models.

Purpose of the Study:

  • To propose and evaluate a "megafund" financial structure for de-risking biomedical innovation.
  • To assess the feasibility and potential returns of a diversified portfolio approach to funding biomedical programs.

Main Methods:

  • A simulation model was developed using historical data for new molecular entities in oncology (1990-2011).
  • The model assessed a financial structure involving a single entity funding a portfolio of programs at various development stages.
  • Financial engineering techniques, including securitization, were incorporated to enhance capital raising capabilities.

Main Results:

  • Simulations indicate that megafunds of $5–15 billion can yield average investment returns of 8.9–11.4% for equity holders.
  • Returns for 'research-backed obligation' holders are projected at 5–8%.
  • These returns, while lower than venture-capital hurdles, are attractive to large institutional investors.

Conclusions:

  • The proposed megafund structure can mitigate risk in biomedical innovation through portfolio diversification and innovative financing.
  • Debt issuance and securitization enable access to larger pools of patient capital.
  • This model presents a viable strategy for attracting institutional investment into high-risk, high-reward biomedical research and development.